Kim Mi Kyung, Kim Hye Soon
Department of Internal Medicine, Keimyung University, School of Medicine, Dongsan Hospital, Daegu 42601, Republic of Korea.
Center of Bariatric and Metabolic Surgery, Keimyung University, Dongsan Hospital, Daegu 42601, Republic of Korea.
Biomol Ther (Seoul). 2025 Jan 1;33(1):5-17. doi: 10.4062/biomolther.2024.228. Epub 2024 Dec 19.
Obesity requires treatment as it is associated with health problems such as type 2 diabetes, hypertension, dyslipidemia, cardiovascular diseases, and some cancers, which increase mortality rates. Achieving sufficient weight loss to reduce obesity-related diseases requires a variety of interventions, including comprehensive lifestyle modification of diet and exercise, change in behavior, anti-obesity medications, and surgery. To date, anti-obesity agents with various mechanisms of action have been developed, and mostly reduce energy intake, resulting in weight loss of about 5% to 10% compared to baseline. Recently developed drugs and those currently under development have been shown to reduce body weight by more than 10% and are expected to reduce obesity-related complications. This article summarizes existing and emerging anti-obesity medications, with a particular focus on those evaluated in clinical trials.
肥胖需要治疗，因为它与2型糖尿病、高血压、血脂异常、心血管疾病和某些癌症等健康问题相关，这些问题会增加死亡率。要实现足够的体重减轻以减少与肥胖相关的疾病，需要多种干预措施，包括饮食和运动的全面生活方式改变、行为改变、抗肥胖药物和手术。迄今为止，已经开发出了具有各种作用机制的抗肥胖药物，这些药物大多会减少能量摄入，与基线相比体重减轻约5%至10%。最近开发的药物和目前正在研发的药物已被证明能使体重减轻超过10%，并有望减少与肥胖相关的并发症。本文总结了现有的和新出现的抗肥胖药物，特别关注那些在临床试验中评估过的药物。
